Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

20184,270 citationsJournal Articlebronze Open Access

Authors

Peter Schmid · Queen Mary University of London

Sylvia Adams · New York University

Hope S. Rugo · University of California, San Francisco

Andreas Schneeweiss · University Hospital Heidelberg

Carlos H. Barrios · Hospital São Lucas da PUCRS

Hiroji Iwata · Aichi Cancer Center

Véronique Dièras

Abstract

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).

Topics & Keywords

HER2/EGFR in Cancer Research Cancer Immunotherapy and Biomarkers Advanced Breast Cancer Therapies

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 22, pp. 2108-2121

DOI: 10.1056/nejmoa1809615

Field-Weighted Citation Impact: 190.68

Command Palette

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Authors

Abstract

Topics & Keywords

Publication Details